Compare FRSH & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | VCEL |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2021 | 1996 |
| Metric | FRSH | VCEL |
|---|---|---|
| Price | $9.96 | $44.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $14.86 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 27.7M | 704.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 296.88 | 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $838,809,000.00 | $276,259,000.00 |
| Revenue This Year | $16.30 | $19.40 |
| Revenue Next Year | $14.09 | $18.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.43 | ★ 16.45 |
| 52 Week Low | $6.79 | $28.95 |
| 52 Week High | $14.43 | $48.75 |
| Indicator | FRSH | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 53.25 |
| Support Level | $9.75 | $44.56 |
| Resistance Level | $10.69 | N/A |
| Average True Range (ATR) | 0.51 | 1.73 |
| MACD | -0.04 | -0.53 |
| Stochastic Oscillator | 17.29 | 7.40 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.